Full Title: The phase III prospective, multi-centre, open-label, 2 arm study for evaluation of 2 durations of adjuvant treatment with tyrosine kinase inhibitor imatinib mesylate for operable gastrointestinal stromal cell tumour (GIST) with high risk for recurrence/ Three versus five years of adjuvant imatinib as treatment of patients with operable GIST with a high risk of recurrence: A randomised phase III multi-centre study by the Scandinavian Sarcoma Group
Phase: Phase 3
If you have a GIST that has a high risk of returning, you may be given chemotherapy after surgery. Chemotherapy given for this reason is called adjuvant therapy. The most common drug used for adjuvant therapy in GIST is imatinib. Imatinib is a tyrosine kinase inhibitor (TKI). It works by blocking the signals in the cancer cells that tell them to grow. This trial is trying to find out whether it is better to give patients adjuvant imatinib for three years or five years after surgery.